TDMS Study 05063-01 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
PHENYLBUTAZONE
NTP Experiment-Test: 05063-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/08/94
Route: GAVAGE Time: 19:21:04
Facility: TSI Mason Research
Chemical CAS #: 50-33-9
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund Sacrifice 14 9 14
Natural Death 5 5 14
Accident 1
Survivors
Terminal Sacrifice 30 35 21
Natural Death 1
Terminal Sacrifice 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (50) (9) (50)
Adenocarcinoma 1 (2%)
Leiomyosarcoma 1 (11%)
Liver (50) (27) (50)
Neoplastic Nodule 1 (2%) 2 (7%)
Mesentery (2) (5) (10)
Sarcoma 1 (20%)
Pancreas (50) (9) (50)
Adenoma 1 (2%)
Salivary Glands (50) (7) (50)
Stomach, Forestomach (49) (49) (49)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50) (49) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (7) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (50)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Adrenal Gland, Medulla (50) (50) (50)
Pheochromocytoma NOS 1 (2%)
Pheochromocytoma Benign 3 (6%) 1 (2%) 2 (4%)
Pituitary Gland (48) (49) (50)
Pars Distalis, Adenoma 30 (63%) 24 (49%) 21 (42%)
Page 2
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pars Distalis, Adenoma, Multiple 1 (2%)
Thyroid Gland (50) (49) (50)
C-Cell, Adenoma 2 (4%) 4 (8%)
C-Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (36) (11) (41)
Adenoma 5 (14%) 4 (36%)
Carcinoma 2 (18%) 2 (5%)
Squamous Cell Carcinoma 1 (9%)
Ovary (50) (14) (50)
Granulosa Cell Tumor Malignant 1 (7%)
Granulosa Cell Tumor Benign 1 (2%)
Uterus (50) (17) (50)
Basosquamous Tumor Malignant 1 (6%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 15 (30%) 7 (41%) 12 (24%)
Polyp Stromal, Multiple 1 (2%)
Sarcoma Stromal 2 (4%) 3 (18%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (6) (48)
Lymph Node (50) (15) (49)
Lymph Node, Mandibular (42) (5) (37)
Squamous Cell Carcinoma, Metastatic,
Zymbal's Gland 1 (2%)
Lymph Node, Mesenteric (50) (13) (46)
Spleen (50) (50) (50)
Thymus (42) (8) (38)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (46) (18) (40)
Adenocarcinoma 1 (2%) 1 (6%)
Fibroadenoma 18 (39%) 8 (44%) 7 (18%)
Fibroadenoma, Multiple 4 (9%) 7 (39%)
Skin (50) (12) (49)
Page 3
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Carcinosarcoma 1 (8%)
Squamous Cell Papilloma 1 (8%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (8%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (1)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (10) (50)
Glioma Benign 1 (10%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (20) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma, Metastatic, Adrenal Gland 1 (5%)
Sarcoma Stromal, Metastatic, Uterus 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Zymbal's Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (2)
Carcinoma 2 (100%)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Carcinoma 1 (2%)
Transitional Epithelium, Carcinoma 2 (4%)
Urinary Bladder (50) (49) (49)
Page 4
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Leukemia Mononuclear 11 (22%) 6 (12%) 4 (8%)
Mesothelioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 46 46 36
Total Primary Neoplasms 103 84 60
Total Animals with Benign Neoplasms 43 39 35
Total Benign Neoplasms 84 62 47
Total Animals with Malignant Neoplasms 19 16 12
Total Malignant Neoplasms 19 22 12
Total Animals with Metastatic Neoplasms 2 1
Total Metastatic Neoplasm 3 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund Sacrifice 11 13 16
Natural Death 6 16 7
Accident 1
Survivors
Terminal Sacrifice 32 20 27
Terminal Sacrifice 1
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (21) (49)
Serosa, Sarcoma, Metastatic, Spleen 1 (5%)
Intestine Small, Duodenum (50) (23) (49)
Serosa, Ileum, Sarcoma, Metastatic, Spleen 1 (4%)
Intestine Small, Ileum (50) (21) (49)
Lymphoid Nodule, Fibrosarcoma, Metastatic,
Mammary Gland 1 (2%)
Liver (50) (50) (50)
Neoplastic Nodule 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Serosa, Sarcoma, Metastatic, Spleen 1 (2%)
Serosa, Sarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Mesentery (4) (5) (3)
Sarcoma, Metastatic, Spleen 1 (20%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (33%)
Pancreas (50) (27) (50)
Adenoma 3 (6%) 3 (11%) 4 (8%)
Sarcoma, Metastatic, Spleen 1 (4%)
Salivary Glands (49) (23) (49)
Stomach (50) (50) (50)
Stomach, Forestomach (50) (50) (50)
Serosa, Sarcoma, Metastatic, Spleen 1 (2%)
Serosa, Glandular, Sarcoma, Metastatic,
Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (20) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (50) (49) (50)
Adrenal Gland, Cortex (50) (49) (50)
Medulla, Osteosarcoma, Metastatic, Bone 1 (2%)
Adrenal Gland, Medulla (50) (48) (49)
Pheochromocytoma Malignant 4 (8%) 2 (4%) 2 (4%)
Pheochromocytoma Complex 1 (2%) 2 (4%)
Pheochromocytoma Benign 9 (18%) 13 (27%) 12 (24%)
Pheochromocytoma Benign, Multiple 2 (4%) 1 (2%)
Bilateral, Pheochromocytoma NOS 1 (2%)
Bilateral, Pheochromocytoma Benign 5 (10%) 4 (8%) 7 (14%)
Islets, Pancreatic (50) (22) (50)
Adenoma 2 (4%) 1 (5%)
Carcinoma 2 (4%)
Pituitary Gland (48) (26) (47)
Pars Distalis, Adenoma 13 (27%) 9 (35%) 20 (43%)
Pars Distalis, Adenoma, Multiple 3 (6%) 1 (4%) 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (49) (21) (49)
C-Cell, Adenoma 6 (12%) 1 (5%) 2 (4%)
C-Cell, Carcinoma 1 (2%) 1 (5%)
Follicular Cell, Adenoma 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Lipoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (49) (50)
Serosa, Sarcoma, Metastatic, Spleen 1 (2%)
Serosa, Sarcoma, Metastatic, Uncertain
Primary Site 1 (2%)
Preputial Gland (43) (25) (47)
Adenocarcinoma 1 (4%) 1 (2%)
Adenoma 2 (5%) 4 (16%)
Carcinoma 1 (2%)
Sarcoma 1 (2%)
Prostate (50) (21) (46)
Page 8
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Seminal Vesicle (49) (36) (47)
Serosa, Sarcoma, Metastatic, Spleen 1 (3%)
Testes (50) (49) (50)
Bilateral, Interstitial Cell, Adenoma 35 (70%) 32 (65%) 38 (76%)
Interstitial Cell, Adenoma 11 (22%) 9 (18%) 10 (20%)
Tunic, Sarcoma, Metastatic, Spleen 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (20) (50)
Lymph Node (50) (26) (50)
Mediastinal, Sarcoma, Metastatic, Spleen 1 (4%)
Lymph Node, Mandibular (44) (18) (41)
Fibrosarcoma, Metastatic 1 (2%)
Lymph Node, Mesenteric (47) (19) (49)
Spleen (50) (32) (50)
Sarcoma 1 (3%) 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Thymus (42) (18) (42)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (21) (8) (24)
Fibroadenoma 2 (10%) 5 (63%) 3 (13%)
Skin (50) (27) (49)
Basal Cell Carcinoma 1 (2%)
Basosquamous Tumor Malignant 1 (2%)
Keratoacanthoma 2 (4%) 1 (4%) 1 (2%)
Squamous Cell Papilloma 1 (4%)
Sebaceous Gland, Adenoma 1 (4%)
Subcutaneous Tissue, Fibroma 3 (6%) 3 (11%) 4 (8%)
Subcutaneous Tissue, Fibrosarcoma 2 (4%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (4%)
Subcutaneous Tissue, Myxosarcoma 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (21) (50)
Scapula, Osteosarcoma 1 (5%)
Skeletal Muscle (1) (3) (1)
Osteosarcoma, Extension, Metastatic 1 (33%)
Diaphragm, Sarcoma, Metastatic, Uncertain
Page 9
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM - cont
Primary Site 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (20) (50)
Astrocytoma Malignant 1 (2%) 1 (5%) 1 (2%)
Granular Cell Tumor Benign 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (34) (50)
Alveolar/Bronchiolar Adenoma 3 (9%)
Alveolar/Bronchiolar Carcinoma 2 (4%)
Fibrosarcoma, Metastatic, Ear 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (3%)
Pheochromocytoma Malignant, Metastatic 1 (3%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (3) (1)
Pinna, Fibrosarcoma 1 (33%)
Eye (1) (3)
Lids, Fibroma 1 (100%)
Harderian Gland (1)
Adenoma 1 (100%)
Zymbal's Gland (3) (1) (1)
Carcinoma 2 (67%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (50)
Bilateral, Renal Tubule, Adenoma 1 (2%)
Renal Tubule, Adenoma 2 (4%)
Renal Tubule, Carcinoma 1 (2%)
Urinary Bladder (45) (22) (48)
Transitional Epithelium, Papilloma 2 (9%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Leukemia Mononuclear 2 (4%) 2 (4%) 2 (4%)
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS - cont
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Lymphocytic 1 (2%)
Mesothelioma Benign 1 (2%)
Mesothelioma Malignant 3 (6%) 4 (8%) 3 (6%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05063-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC PHENYLBUTAZONE Date: 09/08/94
Route: GAVAGE Time: 19:21:04
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 0.05G/KG 0.1 G/KG
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 50 48 50
Total Primary Neoplasms 130 112 125
Total Animals with Benign Neoplasms 49 47 49
Total Benign Neoplasms 105 96 108
Total Animals with Malignant Neoplasms 21 14 14
Total Malignant Neoplasms 25 15 17
Total Animals with Metastatic Neoplasms 2 5 2
Total Metastatic Neoplasm 3 17 8
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------